{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:18:06Z","timestamp":1791883086623,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jval.2026.04.005","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:31:44Z","timestamp":1777581104000},"page":"1580-1589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Do Quality-Adjusted-Life-Year-Based Cost-Effectiveness Analyses Discriminate Against Disabled Patients? A Theoretical and Empirical Analysis"],"prefix":"10.1016","volume":"29","author":[{"given":"Yue","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Vanness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongchao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2026.04.005_bib1","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"key":"10.1016\/j.jval.2026.04.005_bib2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.socscimed.2018.07.004","article-title":"Quantifying life: understanding the history of quality-adjusted life-years (QALYs)","volume":"211","author":"MacKillop","year":"2018","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.jval.2026.04.005_bib3","series-title":"Rationing NHS: Princ Pragmatism","author":"New","year":"1996"},{"issue":"3","key":"10.1016\/j.jval.2026.04.005_bib4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/jme.13.3.117","article-title":"QALYfying the value of life","volume":"13","author":"Harris","year":"1987","journal-title":"J Med Ethics"},{"issue":"1","key":"10.1016\/j.jval.2026.04.005_bib5","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1186\/s12913-020-05521-x","article-title":"QALY-time: experts\u2019 view on the use of the quality-adjusted LIFE year in COST-effectiveness analysis in palliative care","volume":"20","author":"Wichmann","year":"2020","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"10.1016\/j.jval.2026.04.005_bib6","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s11136-021-03052-4","article-title":"The QALY is ableist: on the unethical implications of health states worse than dead","volume":"31","author":"Schneider","year":"2022","journal-title":"Qual Life Res"},{"issue":"2","key":"10.1016\/j.jval.2026.04.005_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.36469\/001c.83387","article-title":"QALYs: the math doesn\u2019t work","volume":"10","author":"Sawhney","year":"2023","journal-title":"J Health Econ Outcomes Res"},{"issue":"9","key":"10.1016\/j.jval.2026.04.005_bib8","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1377\/hlthaff.2021.00343","article-title":"Controversy over using quality-adjusted life-years in cost-effectiveness analyses: a systematic literature review","volume":"40","author":"Rand","year":"2021","journal-title":"Health Aff (Millwood)"},{"issue":"2","key":"10.1016\/j.jval.2026.04.005_bib12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/14737167.2023.2283584","article-title":"Alternative approaches to measuring value: an update on innovative methods in the context of the United States Medicare drug price negotiation program","volume":"24","author":"DiStefano","year":"2024","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"24","key":"10.1016\/j.jval.2026.04.005_bib13","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1001\/jama.2023.8695","article-title":"Congress\u2019 misguided plan to ban QALYs","volume":"329","author":"Rand","year":"2023","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jval.2026.04.005_bib14","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jval.2024.03.011","article-title":"Do quality-adjusted life years discriminate against the elderly? An empirical analysis of published cost-effectiveness analyses","volume":"27","author":"Xie","year":"2024","journal-title":"Value Health"},{"issue":"24","key":"10.1016\/j.jval.2026.04.005_bib15","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1001\/jama.2018.6072","article-title":"QALYs in 2018\u2014advantages and concerns","volume":"319","author":"Neumann","year":"2018","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jval.2026.04.005_bib16","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jval.2024.04.018","article-title":"The value of the quality-adjusted life years","volume":"27","author":"Willke","year":"2024","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2026.04.005_bib17","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/1475-6773.14116","article-title":"Alternatives to the quality-adjusted life year: how well do they address common criticisms?","volume":"58","author":"Rand","year":"2023","journal-title":"Health Serv Res"},{"issue":"10","key":"10.1016\/j.jval.2026.04.005_bib18","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s40273-023-01302-6","article-title":"An alternative measure of health for value assessment: the equal value life-year","volume":"41","author":"Campbell","year":"2023","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.jval.2026.04.005_bib19","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jval.2019.10.014","article-title":"Health years in total: a new health objective function for cost-effectiveness analysis","volume":"23","author":"Basu","year":"2020","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jval.2026.04.005_bib20","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jval.2023.11.009","article-title":"Logical inconsistencies in the health years in total and equal value of life-years gained","volume":"27","author":"Paulden","year":"2024","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2026.04.005_bib21","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/jar.13056","article-title":"Outcome measures for economic evaluations and cost-effectiveness analyses of interventions for people with intellectual disabilities: a methodological systematic review","volume":"36","author":"Benedetto","year":"2023","journal-title":"J Appl Res Intellect Disabil"},{"key":"10.1016\/j.jval.2026.04.005_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2025.100562","article-title":"An empirical investigation into concerns over quality-adjusted life-years: a review of cost-effectiveness analyses in oncology","volume":"43","author":"Raymakers","year":"2025","journal-title":"J Cancer Policy"},{"key":"10.1016\/j.jval.2026.04.005_bib24","series-title":"World Report on Disability","year":"2011"},{"issue":"14","key":"10.1016\/j.jval.2026.04.005_bib26","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.21037\/atm-21-3132","article-title":"Cost-effectiveness of Anbainuo plus methotrexate compared to conventional disease-modifying antirheumatic drugs for rheumatoid arthritis patients in China","volume":"9","author":"Tian","year":"2021","journal-title":"Ann Transl Med"},{"issue":"7","key":"10.1016\/j.jval.2026.04.005_bib27","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1080\/13696998.2017.1307205","article-title":"Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators","volume":"20","author":"Jansen","year":"2017","journal-title":"J Med Econ"},{"issue":"7","key":"10.1016\/j.jval.2026.04.005_bib28","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3899\/jrheum.160941","article-title":"The cost-effectiveness of sequences of biological disease-modifying antirheumatic drug treatment in England for patients with rheumatoid arthritis who can tolerate methotrexate","volume":"44","author":"Stevenson","year":"2017","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.jval.2026.04.005_bib29","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1111\/dom.14162","article-title":"Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real-world evidence","volume":"22","author":"McEwan","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.jval.2026.04.005_bib30","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/dom.14308","article-title":"The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: an economic evaluation using data from the DECLARE-TIMI 58 trial","volume":"23","author":"McEwan","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.jval.2026.04.005_bib31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jval.2016.08.734","article-title":"Costs and outcomes of increasing access to bariatric surgery: cohort study and cost-effectiveness analysis using electronic health records","volume":"20","author":"Gulliford","year":"2017","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jval.2026.04.005_bib32","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3111\/13696998.2011.579213","article-title":"Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK","volume":"14","author":"Beaudet","year":"2011","journal-title":"J Med Econ"},{"key":"10.1016\/j.jval.2026.04.005_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110625","article-title":"Value of GLP-1 receptor agonists versus long-acting insulins for type 2 diabetes patients with and without established cardiovascular or chronic kidney diseases: a model-based cost-effectiveness analysis using real-world data","volume":"198","author":"Yang","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"issue":"11","key":"10.1016\/j.jval.2026.04.005_bib34","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.2337\/dc19-0381","article-title":"Influence of diabetes complications on HbA1c treatment goals among older U.S. adults: a cost-effectiveness analysis","volume":"42","author":"Shao","year":"2019","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.jval.2026.04.005_bib35","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jval.2017.08.3020","article-title":"Cost-Effectiveness of First-Line sevelamer and lanthanum versus Calcium-Based Binders for hyperphosphatemia of Chronic Kidney Disease","volume":"21","author":"Habbous","year":"2018","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jval.2026.04.005_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002532","article-title":"Cost-effectiveness of multidisciplinary care in mild to moderate chronic kidney disease in the United States: a modeling study","volume":"15","author":"Lin","year":"2018","journal-title":"PLOS Med"},{"key":"10.1016\/j.jval.2026.04.005_bib37","author":"Cohen"},{"issue":"17","key":"10.1016\/j.jval.2026.04.005_bib38","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1200\/JCO.2007.10.7284","article-title":"Cost effectiveness of adjuvant interferon in node-positive melanoma","volume":"25","author":"Cormier","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2026.04.005_bib39","series-title":"Quality-Adjusted Life Years and the Devaluation of Life With Disability","year":"2019"},{"issue":"2","key":"10.1016\/j.jval.2026.04.005_bib40","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jval.2019.08.009","article-title":"What difference does it make? A comparison of health state preferences elicited from the general population and from people with multiple sclerosis","volume":"23","author":"Goodwin","year":"2020","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.jval.2026.04.005_bib41","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.jval.2021.02.012","article-title":"To what extent do patient preferences differ from general population preferences?","volume":"24","author":"Ludwig","year":"2021","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.jval.2026.04.005_bib42","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jval.2023.05.019","article-title":"Whose time trade-off should be used? Anchoring discrete choice experiment latent utilities in health state valuation","volume":"26","author":"Xie","year":"2023","journal-title":"Value Health"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526023983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526023983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:07:58Z","timestamp":1788350878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301526023983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1098301526023983"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2026.04.005","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Do Quality-Adjusted-Life-Year-Based Cost-Effectiveness Analyses Discriminate Against Disabled Patients? A Theoretical and Empirical Analysis","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2026.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}